[法国国家ENDOCAN-COMETE网络对恶性乳色细胞瘤和偏角细胞瘤的建议]
Christelle de la Fouchardière1, Magalie Haissaguerre2, Myriam Decaussin-Petrucci3
1Centre Léon-Bérard, département de cancérologie médicale, 28, rue Laennec, 69008 Lyon, France.
Bulletin du cancer
|August 12, 2023
概括
乳色细胞瘤和偏角细胞瘤是罕见的神经内分泌瘤. 管理需要多学科专家中心,标准化工作和基于遗传学和成像的个性化治疗.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
关键词:
诊断 诊断 诊断 诊断 诊断诊断 诊断 诊断 的 诊断后续行动 后续行动恶性偏角质瘤 (paraganglioma) 是一种癌症.恶性发红细胞瘤 (pheochromocytoma) 是一种恶性发红细胞瘤.这种类型的病原体有:Paragangliomes métastatiques.植物染色体细胞体具有转移性转移.建议 建议 建议 建议建议 建议 建议随之而来的 随之而来的治疗 治疗 治疗治疗方法 治疗方法更多相关视频
08:55A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
Published on: April 17, 2019
17.7K
08:57Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
Published on: May 17, 2024
2.0K
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
204
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
204
